Dual-Modality Imaging of Virotherapy

Information

  • Research Project
  • 7052212
  • ApplicationId
    7052212
  • Core Project Number
    R43CA119454
  • Full Project Number
    1R43CA119454-01
  • Serial Number
    119454
  • FOA Number
  • Sub Project Id
  • Project Start Date
    6/14/2006 - 19 years ago
  • Project End Date
    5/31/2007 - 18 years ago
  • Program Officer Name
    MENKENS, ANNE E
  • Budget Start Date
    6/14/2006 - 19 years ago
  • Budget End Date
    5/31/2007 - 18 years ago
  • Fiscal Year
    2006
  • Support Year
    1
  • Suffix
  • Award Notice Date
    6/14/2006 - 19 years ago
Organizations

Dual-Modality Imaging of Virotherapy

[unreadable] DESCRIPTION (provided by applicant): Conditionally replicative adenoviruses (CRAds) represent an important novel approach for cancer therapy. CRAd agents are designed to specifically replicate in and kill tumor cells to yield an effective yet safe therapeutic outcome. Although their great potential has awarded them rapid translation into human clinical trials where the safety of CRAds have been clearly highlighted, little data have been obtained with regards to the critical functions of CRAds efficient infection of tumor cells, tumor-specific replication, and lateral spread. Without deeper understanding of the nature of these replicative agents especially in a patient context, further development of CRAds would be greatly hindered. The crux of a general dilemma in the virotherapy field is lack of a monitoring system compatible with replicative agents. Unfortunately, most gene therapy vector detection schemes have been specifically designed to assess gene expression. These modalities are unsuitable for monitoring of CRAds because their very nature is to kill infected tumor cells, a concept at odds with the notion of viable transgene expression. Furthermore, reporters by themselves cannot accurately depict the underlying level of replication as well as true physical distribution of viral progeny, two crucial functions of replicative agents. Clinical trials to date have had to rely on traditional histological analysis of biopsy specimens which are error-prone and cannot portray the multiplicative nature of CRAds. The ideal monitoring system for CRAds should embody the following features: (1) report the level of viral replication, (2) allow direct detection of viral spread, (3) permit dynamic detection of viral activity, (4) minimally perturb replication and spread efficiency of the virus, and (5) possess the power for noninvasive detection. To address this issue, we hypothesized that a genetic adenovirus labeling system using a structural reporter fusion protein would dynamically represent viral replication and spread. We propose adenovirus capsid labeling with pIX-HSV-tkto allow PET-based imaging. In addition, labeling with both EGFP and HSV-tk would allow imaging analysis by both optical and PET-based methods. It is evident that a monitoring system for CRAds is needed for advancing the field. A genetic structural labeling system for adenovirus would offer noninvasive dynamic detection of replication and spread. Not only would this system be indispensable in developing advanced CRAds, it would also be applicable for monitoring CRAd therapy in patients. [unreadable] [unreadable]

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    VECTORLOGICS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    BIRMINGHAM
  • Organization State
    AL
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    35294
  • Organization District
    UNITED STATES